An exploratory study for development of hemodynamic indicators for clinical effectiveness of methylphenidate in children with AD/HD

Not Applicable

• Conditions: Attention-deficit/hyperactivity disorder

• Registration Number: JPRN-UMIN000001542
• Lead Sponsor: Shimada Ryoiku Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-12-02
• Study Completion: 2011-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. A patient with severe anxiety or agitation. 2. A patient with glaucoma. 3. A patient with thyroidal dysfunction 4. A patient with arrythmia or abnormal blood pressure. 5. A patient with history of allergic reaction or severe side effects with methylphenidate. 6. A patient with severe mood disorder 7. A patient with motor tics, Tourette's syndrome, or family history of Tourette's syndrome. 8. A patient with pheochromocytoma. 9. A patient who receives medication of MAO inhibitor. 10. A patient with epilepsy. 11. A patient with schizophrenia, psychotic disorders, bipolar disorder. 12. A patient with history of drug abuse or alcohol dependence. 13. A patient with significant mental retardation (FIQ<70, WISC-III).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relation between hemodynamic changes detected by near-infrared spectroscopy and difference of AD/HD symptoms.

Secondary Outcome Measures

Name	Time	Method
1) Assessment of behavioral disturbances(CBCL) 2) Assessment of general function(GAF) 3) Assessment of comorbidities(SCAS,CDRS,PARS) 4) Assessment of self-estimate(JSSC)